查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1751304

数位治疗市场规模、份额、趋势分析报告：按应用、最终用途、地区、细分市场预测，2025-2030 年

Digital Therapeutics Market Size, Share & Trends Analysis Report By Application (Diabetes, Obesity), By End Use (Patients, Providers, Payers, Employers), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

数位治疗市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球数位治疗市场规模预计到2030年将达到325亿美元，2025年至2030年期间的复合年增长率为27.77%。

推动市场成长的主要因素是智慧型手机的广泛普及。医疗服务提供者和患者能够以可负担的价格获得数位医疗技术、对整合医疗系统的需求不断增长以及以患者为中心的医疗服务是推动市场成长的关键因素。此外，全球化的加剧和生活方式的改变，例如吸烟率上升、营养不良、缺乏运动和饮酒消费量增加，也增加了罹患慢性病的可能性。

市场扩张主要得益于数位疗法的日益普及以及美国食品药物管理局（FDA）等主要监管机构的支持措施。例如，2020年4月，美国食品药物管理局（FDA）发布了指南，旨在加强数位治疗设备在精神疾病患者中的广泛应用。此外，根据Kepios的数据，全球网路用户的年增长率为7.6%，相当于每天新增约90万网路用户。儘管已开发国家和开发中国家的智慧型手机和网路使用率都很高，但非洲和南亚等地区仍面临经济制约，需要迎头赶上。

慢性病盛行率的上升也推动了市场的成长。根据美国疾病管制与预防中心（CDC）下属的国家慢性病预防与健康促进中心的数据，每10个美国成年人中就有6人患有慢性病，每10个成年人中就有4人患有两种或两种以上的慢性病。例如，Teladoc Health, Inc.于2022年2月推出了Chronic Care Complete，这是一款旨在改善医疗保健效果的慢性病管理解决方案。心血管疾病、癌症、糖尿病、慢性肾臟病、慢性肺病和阿兹海默症已被确定为美国死亡和残疾的主要原因。

数位疗法已成为治疗各种健康状况的重要选择，这主要归功于业界主要企业制定的客製化治疗计划和策略性倡议。这些措施包括併购、取得监管机构核准、推出新产品、建立伙伴关係等。此外，心血管疾病、糖尿病和焦虑症等慢性病的发生率不断上升，促使市场主要参与者投资于数位治疗解决方案。许多公司正在开发专注于焦虑管理的数位治疗产品，其中许多产品处于不同的研发阶段。这代表着巨大的市场成长机会。例如，2023 年 8 月，Welldoc 透露，其用于糖尿病管理的 BlueStar 数位健康解决方案已获得第 10 次 FDA 510(k) 批准。此次批准将使 BlueStar 能够将联网的胰岛素给药资讯纳入客製化的推注Bolus给药建议中。

数位治疗市场报告重点

  • 预计糖尿病领域将在 2024 年占据市场主导地位，市场占有率最大，为 29.75%，并在预测期内实现最快的复合年增长率。
  • 预计患者部门将在 2024 年占据最大的市场占有率，达到 34.50%，并在预测期内实现最快的成长率。
  • 北美数位治疗产业占据全球市场主导地位，2024 年的收益占有率为 40.11%。

目录

第一章调查方法与范围

第二章执行摘要

第三章数字治疗市场变数、趋势和范围

  • 市场展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 数位治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章 数位治疗市场：应用评估与趋势分析

  • 2024年及2030年的市场占有率
  • 细分仪表板
  • 全球数位治疗市场前景
  • 糖尿病
  • 肥胖
  • 心血管疾病（CVD）
  • 呼吸系统疾病
  • 禁止抽烟
  • 中枢神经系统 (CNS) 疾病
  • 其他的

第五章数位治疗市场：最终用途估计与趋势分析

  • 2024年及2030年的市场占有率
  • 细分仪表板
  • 全球数位治疗市场前景
  • 病人
  • 提供者
  • 付款人
  • 雇主
  • 其他的

第六章 数位治疗市场：区域估计和趋势分析、按应用和最终用途

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 市场规模、预测趋势分析，2018 年至 2030 年：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特
    • 其他中东和非洲地区

第七章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 公司简介
    • OMADA HEALTH, INC.
    • Welldoc, Inc.
    • 2Morrow, Inc
    • Livongo Health, Inc.（Teladoc Health, Inc.）
    • Propeller Health（ResMed）
    • Fitbit LLC
    • Mango Health
    • CANARY HEALTH
    • Noom, Inc.
    • Pear Therapeutics, Inc.
    • Akili Interactive Labs, Inc.
    • HYGIEIA
    • DarioHealth Corp.
    • BigHealth
    • GAIA AG
    • Limbix Health, Inc.
Product Code: GVR-1-68038-768-1

Digital Therapeutics Market Growth & Trends:

The global digital therapeutics market size is estimated to reach USD 32.5 billion by 2030, registering to grow at a CAGR of 27.77% from 2025 to 2030 according to a new report by Grand View Research, Inc. The primary driver for expanding the market growth is the increased use of smartphones. The affordability of digital health technologies for healthcare providers & patients, rising demand for integrated healthcare systems, and care focusing on the patient are key factors fueling the market's growth. Furthermore, the growing globalization and shifts in lifestyle habits, such as higher rates of tobacco use, inadequate nutrition, insufficient physical activity, and rising alcohol consumption, increase the likelihood of chronic disease development.

The market's expansion is significantly influenced by the increasing adoption of digital therapeutics and the supportive initiatives by leading regulatory agencies such as the FDA. For instance, the U.S. FDA provided guidelines in April 2020 to enhance the reach of digital therapeutic devices for people suffering from psychiatric disorders. Furthermore, according to Kepios data, there's a 7.6% annual growth rate in the global internet user base, translating to around 900,000 new internet users daily. While developed and developing nations boast high smartphone and internet usage levels, areas such as Africa and South Asia need to catch up due to their economic limitations.

Increasing prevalence of chronic diseases is also driving the growth of the market. As per the CDC's National Center for Chronic Disease Prevention and Health Promotion, 6 in 10 American adults suffer from a chronic disease, while 4 out of 10 adults have two or more chronic diseases. For instance, in February 2022, Teladoc Health, Inc. launched Chronic Care Complete, a chronic condition management solution to improve healthcare outcomes. Cardiovascular diseases, cancer, diabetes, chronic kidney disease, chronic lung disease, and Alzheimer's have been identified as the leading causes of death and disability in the country.

Digital therapeutics have become an essential option for treating various health conditions, mainly due to customized treatment plans and strategic initiatives by leading companies in the industry. These actions include mergers and acquisitions, clearing regulatory approvals, introducing new products, and establishing partnerships. Moreover, the growing rates of chronic diseases such as cardiovascular disease, diabetes, and anxiety have driven critical players in the market to invest in digital solutions for treatment. Various companies are in the process of developing digital therapeutic products aimed specifically at managing anxiety, with many of these products in different phases of research and development. This presents a significant opportunity for market growth. For instance, In August 2023, Welldoc revealed it had obtained its 10th FDA 510(k) clearance for the BlueStar digital health solution for diabetes management. This clearance allows BlueStar to incorporate connected insulin dosing information into its customized recommendations for bolus insulin dosing.

Digital Therapeutics Market Report Highlights:

  • The diabetes segment dominated the market with largest market share of 29.75% in 2024 and is expected to register the fastest CAGR over the forecast period.
  • The patient segment held the largest market share of 34.50% in 2024 and is anticipated to register the fastest growth rate over the forecast period, owing to patients' rapid adoption of digital therapeutics.
  • North America digital therapeutics industry dominated globally with a revenue share of 40.11% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Application
    • 1.1.2. End Use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Digital Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Digital Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Digital Therapeutics Market: Application Estimates & Trend Analysis

  • 4.1. Application Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Digital Therapeutics Market, by Application Outlook
  • 4.4. Diabetes
    • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5. Obesity
    • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.6. Cardiovascular Disease (CVD)
    • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.7. Respiratory Diseases
    • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.8. Smoking Cessation
    • 4.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.9. Central Nervous System (CNS) Disease
    • 4.9.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Digital Therapeutics Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Digital Therapeutics Market, by End Use Outlook
  • 5.4. Patients
    • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5. Providers
    • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.6. Payers
    • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.7. Employers
    • 5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Digital Therapeutics Market: Regional Estimates & Trend Analysis, By Application, By End Use

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Denmark
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Norway
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.9. Rest of Europe
      • 6.6.9.1. Key country dynamics
      • 6.6.9.2. Regulatory framework/ reimbursement structure
      • 6.6.9.3. Competitive scenario
      • 6.6.9.4. Rest of Europe market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.7. Rest of Asia Pacific
      • 6.7.7.1. Key country dynamics
      • 6.7.7.2. Regulatory framework/ reimbursement structure
      • 6.7.7.3. Competitive scenario
      • 6.7.7.4. Rest of Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Rest of Latin America
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Rest of Latin America market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.5. Rest of MEA
      • 6.9.5.1. Key country dynamics
      • 6.9.5.2. Regulatory framework/ reimbursement structure
      • 6.9.5.3. Competitive scenario
      • 6.9.5.4. Rest of MEA market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Company Profiles
    • 7.3.1. OMADA HEALTH, INC.
      • 7.3.1.1. Company overview
      • 7.3.1.2. Financial performance
      • 7.3.1.3. Product benchmarking
      • 7.3.1.4. Strategic initiatives
    • 7.3.2. Welldoc, Inc.
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Product benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. 2Morrow, Inc
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Livongo Health, Inc. (Teladoc Health, Inc.)
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Propeller Health (ResMed)
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Fitbit LLC
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Mango Health
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. CANARY HEALTH
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Noom, Inc.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Pear Therapeutics, Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Akili Interactive Labs, Inc.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. HYGIEIA
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. DarioHealth Corp.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. BigHealth
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Product benchmarking
      • 7.3.14.4. Strategic initiatives
    • 7.3.15. GAIA AG
      • 7.3.15.1. Company overview
      • 7.3.15.2. Financial performance
      • 7.3.15.3. Product benchmarking
      • 7.3.15.4. Strategic initiatives
    • 7.3.16. Limbix Health, Inc.
      • 7.3.16.1. Company overview
      • 7.3.16.2. Financial performance
      • 7.3.16.3. Product benchmarking
      • 7.3.16.4. Strategic initiatives

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 List of abbreviation
  • TABLE 3 North America digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • TABLE 4 North America digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 5 North America digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 7 U.S. macro dynamics
  • TABLE 8 U.S. digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 9 U.S. digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 10 Canada macro dynamics
  • TABLE 11 Canada digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 12 Canada digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 13 Mexico macro dynamics
  • TABLE 14 Mexico digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 15 Mexico digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 16 Europe digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • TABLE 17 Europe digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 18 Europe digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 19 UK macro dynamics
  • TABLE 20 UK digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 21 UK digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 22 Germany macro dynamics
  • TABLE 23 Germany digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 24 Germany digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 25 France macro dynamics
  • TABLE 26 France digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 27 France digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 28 Italy macro dynamics
  • TABLE 29 Italy digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 30 Italy digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 31 Spain macro dynamics
  • TABLE 32 Spain digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 33 Spain digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 34 Denmark macro dynamics
  • TABLE 35 Denmark digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 36 Denmark digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 37 Sweden macro dynamics
  • TABLE 38 Sweden digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 39 Sweden digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 40 Norway macro dynamics
  • TABLE 41 Norway digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 42 Norway digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 43 Asia Pacific digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • TABLE 44 Asia Pacific digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 45 Asia Pacific digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 46 Asia Pacific digital therapeutics market estimates and forecasts, by therapeutic application, 2018 - 2030 (USD Million)
  • TABLE 47 Japan macro dynamics
  • TABLE 48 Japan digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 49 Japan digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 50 China macro dynamics
  • TABLE 51 China digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 52 China digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 53 India macro dynamics
  • TABLE 54 India digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 55 India digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 56 Australia Macro dynamics
  • TABLE 57 Australia digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 58 Australia digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 59 Thailand macro dynamics
  • TABLE 60 Thailand digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 61 Thailand digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 62 South Korea macro dynamics
  • TABLE 63 South Korea digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 64 South Korea digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 65 Latin America digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • TABLE 66 Latin America digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 67 Latin America digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 68 Brazil macro dynamics
  • TABLE 69 Brazil digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 70 Brazil digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 71 Argentina macro dynamics
  • TABLE 72 Argentina digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 73 Argentina digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 74 MEA digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • TABLE 75 MEA digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 76 MEA digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 77 South Africa macro dynamics
  • TABLE 78 South Africa digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 79 South Africa digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 80 Saudi Arabia Macro dynamics
  • TABLE 81 Saudi Arabia digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 82 Saudi Arabia digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 83 UAE Macro dynamics
  • TABLE 84 UAE digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 85 UAE digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 86 Kuwait Macro dynamics
  • TABLE 87 Kuwait digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 88 Kuwait digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 89 Key company heat map analysis/company position analysis

List of Figures

  • FIG. 1 Market segmentation
  • FIG. 2 Market research process
  • FIG. 3 Estimation methodology
  • FIG. 4 Data triangulation techniques
  • FIG. 5 Primary research pattern
  • FIG. 6 Market research approaches
  • FIG. 7 Value-chain-based sizing & forecasting
  • FIG. 8 QFD modeling for market share assessment
  • FIG. 9 Market formulation & validation
  • FIG. 10 Commodity flow analysis
  • FIG. 11 Digital therapeutics market snapshot, 2024 (USD Million)
  • FIG. 12 Segment snapshot
  • FIG. 13 Competitive landscape snapshot
  • FIG. 14 Parent market outlook
  • FIG. 15 Ancillary market outlook
  • FIG. 16 Digital Therapeutics market dynamics
  • FIG. 17 Digital therapeutics market driver impact
  • FIG. 18 Annual cost per person (USD) for key chronic conditions & by no. of co-morbidities
  • FIG. 19 Top countries by smartphone users, 2021
  • FIG. 20 Digital therapeutics market restraint impact
  • FIG. 21 Market participation categorization
  • FIG. 22 Market leaders and innovators
  • FIG. 23 Company market position analysis
  • FIG. 24 Major deals & strategic alliances analysis
  • FIG. 25 Digital therapeutics market: Application movement analysis
  • FIG. 26 Digital therapeutics Market: Application dashboard
  • FIG. 27 Global diabetes market, 2018 - 2030 (USD Million)
  • FIG. 28 Global obesity market, 2018- 2030 (USD Million)
  • FIG. 29 Global CVD market, 2018- 2030 (USD Million)
  • FIG. 30 Global respiratory diseases market, 2018 - 2030 (USD Million)
  • FIG. 31 Global smoking cessation market, 2018 - 2030 (USD Million)
  • FIG. 32 Global CNS diseases market, 2018- 2030 (USD Million)
  • FIG. 33 Global others market, 2018- 2030 (USD Million)
  • FIG. 34 Digital therapeutics market: End Use movement analysis
  • FIG. 35 Digital therapeutics market: End Use dashboard
  • FIG. 36 Global patients market, 2018- 2030 (USD Million)
  • FIG. 37 Global providers market, 2018 - 2030 (USD Million)
  • FIG. 38 Global payers market, 2018 - 2030 (USD Million)
  • FIG. 39 Global employers market, 2018 - 2030 (USD Million)
  • FIG. 40 Global other end uses market, 2018- 2030 (USD Million)
  • FIG. 41 Regional marketplace: Key takeaways
  • FIG. 42 North America: SWOT analysis
  • FIG. 43 North America digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 44 U.S. digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 45 Canada digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 45 Mexico digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 46 Europe: SWOT analysis
  • FIG. 47 Europe digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 48 UK digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 49 Germany digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 50 France digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 51 Italy digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 52 Spain digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 53 Sweden digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 54 Norway digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 55 Denmark digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 56 Asia Pacific: SWOT analysis
  • FIG. 57 Asia Pacific Digital Therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 58 Japan digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 59 China digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 60 India digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 61 Australia digital therapeutics market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • FIG. 62 South Korea digital therapeutics market estimates and forecasts, 2016 - 2030 (USD Million)
  • FIG. 63 Thailand digital therapeutics market estimates and forecasts, 2016 - 2030 (USD Million)
  • FIG. 64 Latin America: SWOT analysis
  • FIG. 65 Latin America digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 66 Mexico digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 67 Brazil digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 68 Argentina digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 69 Middle East and Africa: SWOT analysis
  • FIG. 70 Middle East and Africa digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 71 South Africa digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 72 Saudi Arabia digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 73 UAE digital therapeutics market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • FIG. 74 Kuwait digital therapeutics market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • FIG. 75 Heat map analysis
  • FIG. 76 List of key emerging companies/technology disruptors/innovators